Apraxia of speech has a significant genetic component, particularly in children. Recent research finds that roughly 1 in 3 children with childhood apraxia of speech (CAS) carry an identifiable genetic variant that explains their condition. But genetics isn’t the whole story. Apraxia in adults is most often caused by stroke or brain injury, not inherited factors.
How Strong Is the Genetic Link?
The evidence for a genetic basis in childhood apraxia of speech is substantial. In a large study published in Molecular Psychiatry, researchers found high-confidence genetic variants in 26% of one group of children with CAS and 33% of a second group. Combined, the diagnostic yield reached 37%, meaning more than a third of children tested had a single-gene explanation for their speech disorder. These weren’t subtle statistical associations. They were specific, identifiable changes in individual genes that disrupt how the brain develops speech motor planning.
Family history data reinforces this picture. In a study of families with children suspected of having CAS, 86% reported at least one nuclear family member with a speech or language disorder. Fifty-nine percent of the children had at least one affected parent. That said, the specific pattern of CAS itself was less common among siblings, suggesting that while speech and language vulnerabilities clearly run in families, the exact way they show up can vary from one person to the next.
The FOXP2 Gene and Beyond
FOXP2 is the most well-known gene linked to apraxia of speech. It was first identified in a large multigenerational family (known as the “KE family”) in which half the members carried a FOXP2 mutation and had CAS along with difficulty coordinating mouth movements. FOXP2 acts as a master regulator, controlling the activity of hundreds of other genes involved in brain development. When it’s mutated, it produces a faulty protein that can’t properly bind to DNA and switch those downstream genes on or off. The result is disrupted development of the brain circuits responsible for planning and sequencing speech movements.
Children with FOXP2-related speech disorder don’t just struggle with speech sounds. They often have difficulty planning oral movements on command, along with problems in understanding and using language, reading, spelling, and fine motor skills. They tend to lag behind peers in building their inventory of speech sounds.
But FOXP2 is only one piece of a much larger genetic puzzle. Researchers have now identified more than 30 genes associated with CAS, including SETBP1, SETD1A, DDX3X, KAT6A, CDK13, EBF3, GNAO1, GNB1, MEIS2, POGZ, UPF2, ZNF142, and CREBBP. Many of these genes share a common function: they’re involved in transcriptional regulation, the process by which cells read and use genetic instructions during brain development. This shared pathway suggests that CAS often stems from disruptions in how the brain builds its speech-planning networks during early development, even when the specific gene involved differs from child to child.
Inherited vs. Spontaneous Mutations
Not all genetic causes of apraxia are inherited from a parent. In one major study, 15 of 18 identified genetic variants arose “de novo,” meaning they were new mutations that appeared for the first time in the child rather than being passed down. Only three were inherited. This is an important distinction for families wondering about recurrence risk. A de novo mutation generally means the chance of a sibling being affected is low, while an inherited variant carries a higher probability of appearing again in future children.
Chromosomal changes can also play a role. Deletions or duplications of small segments of chromosomes, such as deletions at 16p11.2 or deletions involving the FOXP1 gene on chromosome 3, have been identified in children with CAS. A translocation affecting the region of chromosome 7 where FOXP2 sits has also been linked to speech delays and oral motor difficulty.
Apraxia as Part of a Broader Condition
CAS sometimes occurs on its own, but it can also appear as one feature of a broader developmental or genetic syndrome. Children with CAS who also have motor difficulties, language delays, or learning challenges beyond what their speech disorder alone would explain are more likely to have an identifiable genetic cause. Current clinical guidance recommends prioritizing these children for genomic testing, since the combination of speech and non-speech difficulties raises the likelihood of finding a specific genetic diagnosis.
CAS affects roughly 1 in 1,000 children. When genetic testing is performed using whole-exome sequencing (which reads the protein-coding portions of a child’s DNA), studies report finding a clear genetic explanation in about 21% to 37% of cases, depending on how the children were selected and how broadly the analysis searched. That means a meaningful portion of children with CAS will get a specific genetic answer, but the majority currently will not, likely because many contributing genes haven’t been discovered yet or because their apraxia involves more complex genetic patterns that current tests don’t fully capture.
Apraxia in Adults Is Usually Not Genetic
Acquired apraxia of speech in adults has a completely different origin. It results from damage to the brain’s speech-planning areas, most commonly from a stroke. Head injuries, brain tumors, and other neurological conditions can also cause it. In these cases, a person who previously spoke normally loses or struggles with speech motor control because of physical damage to brain tissue, not because of an inherited genetic change.
There is one exception worth noting. A progressive form of apraxia of speech can develop in older adults as part of a neurodegenerative disease. In primary progressive apraxia of speech, the brain’s speech motor areas gradually deteriorate over time. This condition is distinct from both childhood apraxia and stroke-related apraxia, and its causes are still being studied, though it is not currently considered a straightforward genetic disorder in the way CAS often is.
What Genetic Testing Can Tell You
If your child has been diagnosed with CAS, genetic testing may provide a specific explanation. The most common approach is whole-exome sequencing or chromosomal microarray analysis, which can detect both single-gene mutations and larger chromosomal deletions or duplications. A positive result can clarify recurrence risk for future pregnancies, connect families with condition-specific support communities, and sometimes guide expectations about what other developmental areas to monitor.
A negative result doesn’t rule out a genetic contribution. It simply means current technology didn’t find a known variant. Given that new CAS-related genes are being identified at an accelerating pace, retesting or reanalysis of existing data in the future may eventually yield an answer for families who don’t get one today.